Showing 191-200 of 218 results for "".
- Evolus: Jeuveau FDA Cleared for Aesthetic Injectionhttps://modernaesthetics.com/news/evolus-jeuveau-fda-cleared-for-aesthetic-injection/2471954/The FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), the lead product from Evolus, Inc., for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. It will be available to physicians this sp
- Bonti's Gateway Neuromodulator Performs Well in Phase 2A Studyhttps://modernaesthetics.com/news/bontis-gateway-neuromodulator-performs-well-in-pase-2a-for-glabellar-lines/2472208/Bonti’s lead product candidate, EB- 001, passed muster in a Phase 2A study for the treatment of glabellar lines. EB-001 is a novel serot
- SkinCeuticals Introduces A.G.E. Interrupter Ultra Serum to Address Sagging Skinhttps://modernaesthetics.com/news/skinceuticals-introduces-age-interrupter-ultra-serum-to-address-sagging-skin/2476036/SkinCeuticals announced the launch of its A.G.E. Interrupter Ultra Serum, a new addition to its A.G.E. line designed to target skin laxity. Sagging skin, often heightened by factors such as rapid weight loss, has become a growing concern among patients seeking dermatologic care. This serum offers
- Johnson & Johnson MedTech Launches Larger-Sized Breast Implants for Post-Mastectomy Reconstructionhttps://modernaesthetics.com/news/johnson-johnson-medtech-launches-larger-sized-breast-implants-for-post-mastectomy-reconstruction/2475365/Johnson & Johnson MedTech has announced the U.S. launch of MENTORTM Memory GelTM Enhanced Breast Implants, a new line of breast implants specifically developed for women undergoing primary or revision reconstruction after mastectomy. The implants, which received FDA appr
- Dr. Jason Bloom Shares Latest Innovations from Korean Skincare on Philadelphia Newscasthttps://modernaesthetics.com/news/dr-jason-bloom-shares-latest-skincare-innovations-from-korean-skincare/2473702/Korean skincare, also known as K-Beauty, has become increasingly popular in the United States as Americans look to achieve “glass” skin. Social media, particularly TikTok, has played a large role in promoting K-Beauty lines and products. Jason Bloom, MD, is the founder
- New Data Demonstrates Long-Term Safety, Efficacy of Galderma’s RelabotulinumtoxinAhttps://modernaesthetics.com/news/new-data-demonstrates-long-term-safety-efficacy-of-galdermas-relabotulinumtoxina/2473698/Galderma presented new phase III data from the READY-4 clinical trial at the American Society for Dermatologic Surgery (ASDS) 2024 Annual Meeting last week. The data demonstrates the long-term safety of RelabotulinumtoxinA (RelfydessTM) for frown lines and crow’s feet after repea
- Cetaphil Launches Rebrand with Debut of ‘For Everyone’s Sensitive Skin’ Campaignhttps://modernaesthetics.com/news/cetaphil-launches-rebrand-with-debut-of-for-everyones-sensitive-skin-campaign/2473689/A popular skincare line debuts “For Everyone’s Sensitive Skin” campaign as part of a rebrand. Cetaphil announced a complete brand “restage,” in a press release earlier this week. The brand is revamping its 77-year-old image with a bold, refreshed visual upgrade. 
- Epicutis® Launches Arctigenin Brightening Treatmenthttps://modernaesthetics.com/news/epicutis-launches-arctigenin-brightening-treatment/2473684/The newest addition to Epicutis’s science-based professional skincare line, which the company says treats skin health and not age, is the Arctigenin Brightening Treatment—a clean, clinically proven skin brightening treatment that Epicutis says dethrones Vitamin C as the reigning brigh
- Allergan Reports Positive Phase 3 Data for New Short-acting Neurotoxinhttps://modernaesthetics.com/news/allergans-trenibotulinumtoxine-bonte-smoothes-glabellar-lines-quickly/2473513/Allergan Aesthetics’ trenibotulinumtoxinE (BoNT/E) performed well for the treatment of moderate to severe glabellar lines, according to topline results from two pivotal Phase 3 studies. BoNT/E is a novel botulinum neurotoxin serotype E with a quick onset of action
- RelabotulinumtoxinA Update from Galdermahttps://modernaesthetics.com/news/relabotulinumtoxina-update-from-galderma/2473504/The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Galderma related to its pending Biologics License Application (BLA) for RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity